Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
Information source: Yonsei University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Laparoscopic Marsupialization of Renal Cyst
Intervention: Ondansetron (Drug); Ramosetron (Drug); Palonosetron (Drug); Normal saline inj (Drug)
Sponsored by: Yonsei University
The aim of this prospective randomized controlled study was to compare the prophylactic
effects of intravenous single dose of ondansetron, ramosetron, and palonosetron on
PCA-related nausea and vomiting after urologic laparoscopic surgery.
Official title: Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention
severity of nausea
the number of vomiting
Minimum age: 20 Years.
Maximum age: 65 Years.
- ASA I or II
- Patients aged (20-65 yr) Undergoing Laparoscopic Nephrectomy
- Patients who want a patient-controlled IV analgesia (IV-PCA)
- History of allergy or hypersensitivity to 5-HT3 antagonist
- History of severe postoperative nausea/vomiting
- Prolonged QT interval on preoperative EKG
- Hypokalemia, Hypomagnesemia
- Intestinal obstruction
- Pregnant female or breast feeding mother
Locations and Contacts
Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea, Republic of
Starting date: August 2010
Last updated: November 16, 2011